1. A medicament for the treatment or prevention of palmar-plantar syndrome (LPS) caused by therapy with a multipurpose kinase inhibitor (MIC) containing a therapeutically effective amount of allopurinol or a pharmaceutically acceptable salt thereof. The drug according to claim 1, where the palmar-plantar syndrome is caused by sunitinib. The drug according to claim 1, where the palmar-plantar syndrome is caused by sorafenib. The medicament according to claim 1, wherein the medicament is intended for topical use, preferably for topical use on the skin of the hands or feet. The medicament according to claim 4, wherein the medicament is a cream, preferably a hydrophilic cream. The drug according to any one of paragraphs. 1-5, where the drug contains from about 1-10% by weight of the composition of allopurinol or its pharmaceutically acceptable salt, preferably from about 1 to about 8%, more preferably from about 2 to about 5% by weight. The medicament according to claim 1, wherein the medicament contains about 3% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof. The use of allopurinol or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of palmar plantar syndrome (LPS) caused by therapy with a multipurpose kinase inhibitor (MIC) .9. The use of allopurinol in the treatment or prevention of palmar-plantar syndrome (LPS) caused by therapy with a multipurpose kinase inhibitor (MIC) .10. The use of allopurinol in the treatment or prevention of palmar-plantar syndrome1. Лекарственное средство для лечения или профилактики ладонно-подошвенного синдрома (ЛПС), вызванного терапией многоцелевым ингибитором киназ (МИК), содержащее терапевтически эффективное количество аллопуринола или его фармацевтически приемлемой соли.2. Лекарственное средство по п.1, где ладонно-подошвенный синдром вызван сунитинибом.3. Лекарственное средство по п.1, где ладонно-подошвенный синдром вызван сорафе
